Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hana Micron (067310) – Additional Listing (Conversion of Domestic Private CB) / 2024-03-26

Posted on March 26, 2024August 2, 2026 By K-STOCK Editor No Comments on [Disclosure] Hana Micron (067310) – Additional Listing (Conversion of Domestic Private CB) / 2024-03-26

Fact Source: Financial Supervisory Service DART

💡 Executive Summary

Hana Micron disclosed the additional listing of 4,062,321 common shares resulting from the conversion of its 16th domestic private convertible bonds (CB), scheduled for listing on March 29, 2024.

📊 Key Disclosure Content & Financial Figures Summary

  1. Company Name: Hana Micron Inc.
  2. Type & Number of Additional Shares: 4,062,321 common shares (Short Code: A067310)
  3. Par Value per Share: KRW 500
  4. Reason for Additional Listing: Conversion of Domestic Private Convertible Bonds (Issue Round/Conversion Date: 16th Round / March 15, 2024)
  5. Issue/Conversion/Exercise Price: KRW 10,632 per share
  6. Listing Date: March 29, 2024
  7. Total Listed Shares After Additional Listing: 52,136,475 common shares (Dividend Base Date: January 1, 2024)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Additional Listing Schedule and Changes in Total Shares

This disclosure announces the additional shares and the listing date resulting from new shares issued through the conversion of convertible bonds. Checking the listing date (March 29, 2024), conversion price (KRW 10,632), and the updated total number of listed shares (52,136,475 shares) is necessary. Further details can be verified through this disclosure and the Korea Exchange KIND system.

📢 Disclaimer & Source Information

Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Disclaimer: This content is provided solely for information purposes and linguistic reference. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific securities. All investment decisions and financial risks rest solely with the investor.

Contact: For compliance inquiries or copyright-related issues, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] LEENO Industrial (058470) – Results of Annual General Meeting of Shareholders / 2024-03-26
Next Post: [Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-03-27

Related Posts

[Disclosure] Hanwha Aerospace (012450) to Hold Investor Relations (IR) for Q1 2025 Earnings Disclosures
[Disclosure] Jusung Engineering (036930) – Withdrawal of Decision on Corporate Spin-off / 2024-10-29 Disclosures
[Disclosure] Samsung Electro-Mechanics (009150) – Future Business/Management Plan (Fair Disclosure) / 2026-07-03 Semiconductors
[Disclosure] Celltrion (068270) – Provisional Consolidated Financial Results / 2025-02-25 Disclosures
[Disclosure] Hanwha Ocean (042660) – Signing of Single Sales/Supply Contract / 2025-02-25 Disclosures
[Disclosure] Hanmi Semiconductor (042700) – Matters Related to Timely Disclosure Obligations (Fair Disclosure) / 2026-01-02 Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme